USPTO serial 79214474
TASLY
Reviewed by CopyMark Law Group
Reg. 5477867Status 709
- Filing date
- Status date
- Registration date
- May 29, 2018
- Examiner
- STRUCK, ROBERT J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TASLY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Tasly Pharmaceutical Group Co., Ltd.
CN
Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
Tasly Pharmaceutical Group Co., Ltd.
CN
Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
Tasly Pharmaceutical Group Co., Ltd.
CN
Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael D. Schumann
Michael D. Schumann Hamre, Schumann, Mueller & Larson, P.C.45 South Seventh StreetSuite 2700Minneapolis, MN 55402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicine for human purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Chemico-pharmaceutical preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Raw material medicine for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Biomedicine for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; pharmaceutical herbs for medical purposes; Prepared Chinese medicine for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Capsules for medicines, namely, capsules sold empty for pharmaceuticals; Pharmaceutical preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Dietetic food and beverages adapted for medical use; bath preparations, medicated; Medical analgesic preparations; preparations for the treatment of burns; Syrups for pharmaceutical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; vitamin preparations; sunburn preparations for pharmaceutical purposes; vaccines; detergents for medical purposes; disinfectants for hygiene purposes; digestives for pharmaceutical purposes; mineral water for medical purposes; Mineral salts for medical purposes; purgatives; meal for pharmaceutical purposes; flour for pharmaceutical purposes; febrifuges; medicinal tea; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; anthelmintics; Pharmaceutical Gelatin, namely, gelatin capsules sold empty for pharmaceuticals ; germicides; greases for medical purposes; chemical preparations for the diagnosis of pregnancy; medicinal oils; medicinal herbs; Lotions for pharmaceutical purposes, namely, anti-bacteria hand washing solution, oral washings, gynecological washings, anorectal washings; Ointments for pharmaceutical purposes, namely, sunburn ointments, anti-inflammatory ointments, hemorrhoidal ointments, frostbite salve for pharmaceutical purposes, eye ointments; Pectin for pharmaceutical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; herbs teas for medicinal purposes; pharmaceutical preparations for skin care; pharmaceutical preparations for treating dandruff; first-aid boxes, filled; medicinal roots; medicinal herbal preparations, namely, tonics medicine; sedatives; soporifics; sugar for medical purposes; Biological preparations for medical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; medical preparations for slimming purposes; by-products of the processing of cereals for dietetic or medical purposes; medicines for dental purposes; Diagnostic preparations for medical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; medicinal drinks; ferments for pharmaceutical purposes; chemical reagents for medical or veterinary purposes; Dietary fiber to aid digestion; enzyme preparations for medical purposes; amino acids for pharmaceutical purposes; mouthwashes for medical purposes; appetite suppressants for medical purposes; adjuvants for medical purposes; Weight-reducing aid, namely, weight management supplements; Medicine for the treatment of sunburns; Food supplements, namely, antioxidants used for medicinal purposes; acne treatment preparation; Medicinal herbal preparations, namely, lysine electuary; oral rehydration salts; Medicinal liquor for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Medicinal herbal preparations, namely, ginseng electuary; Ginseng for medicinal use; Medicinal herbal preparations, namely, medlar; Dietetic beverages adapted for medicinal purposes, namely, weight-reducing tea; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; nutritional food additives for medical purposes in the nature of natural food extracts derived from fish, meat, vegetables, fruits; food for babies; milk powder for infants; air purifying preparations; Medicated animal washes; Veterinary preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; Medicated animal feed; biocides; vermin destroying preparations; sanitary towels; wadding for medical purposes; medical dressings; rubber for dental purposes; teeth filling material; diaper for pets | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
- Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
- Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
- Other trademarks in Class 005
- Similar marks named TASLY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 19, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Feb 1, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Feb 1, 2026 | INPC | INVALIDATION PROCESSED | — |
| Aug 13, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 13, 2024 | C71T | CANCELLED SECTION 71 | — |
| May 29, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Sep 29, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 11, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 11, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 29, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 29, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 13, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 13, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 21, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 10, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 1, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 13, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 12, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 12, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 21, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 20, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 20, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 22, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 1, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 1, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 30, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 29, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 21, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 21, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 17, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |